NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
Clinical Trials
26 trialsNCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04602078 2025-04-24
AUREA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT01326871 2024-06-25
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
Phase 1/2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003907 2023-07-05
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02264990 2021-02-26
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie
Phase 3 Completed
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00454779 2018-10-17
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Amgen
Phase 2 Completed
NCT01809210 2018-03-13
SELECT-3
AstraZeneca
Phase 1 Completed
NCT00201760 2017-12-27
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00942825 2017-05-24
CBP08-02
CanBas Co. Ltd.
Phase 2 Completed
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00463788 2014-02-13
BALI-1
Merck KGaA, Darmstadt, Germany
Phase 2 Completed